(Gene Therapy)(Q & A)
Nancy Barone Kribbs is Senior Vice President, Global Head of Regulatory Affairs at Myrtelle, serving as the head of Global Regulatory Affairs. She joined the company at its inception in 2021 and brings more than 25 years of experience in drug development. Nancy most recently served as Vice President, Head of Regulatory Affairs at Aruvant Sciences where she led the company in European Medicines Agency (EMA) Scientific Advice, development of the Pediatric Investigation Plan, and in obtaining EMA Orphan Drug and PRIME designation for ARU-1801, a lentiviral gene therapy for sickle cell disease. Previously, as Vice President of Regulatory Affairs at Agilis/PTC, Nancy developed gene therapies for rare neurological diseases including AADC deficiency (Upstaza), Friedreich Ataxia and Angelman Syndrome. Also, at Avexis, Nancy worked on the development of Zolgensma, a gene therapy for the rare disease Spinal Muscular Atrophy. In previous years, Nancy led the Cardiovascular portfolio for Regulatory at Sanofi, where her responsibilities included Plavix and Avapro, and at Bristol Myers-Squibb she developed Myalept for Lipodystrophy, a rare metabolic disease. At Cephalon, Nancy was instrumental in the approval of Provigil for the rare CNS disease, narcolepsy. Her earlier career was spent in academic research in sleep disorders, at The Pennsylvania State University and at the University of Pennsylvania Institute of Neurological Sciences, and School of Medicine Department of Psychiatry.
Nancy holds a B.S. in Psychology from Xavier University, and an M.A. and Ph.D. in Experimental Psychology from the University of Toledo. In other pursuits, Nancy is a professional musician, and you might catch her playing trombone at all kinds of events and venues on the east coast.
Nancy is grateful for her opportunity at Myrtelle, to help bring innovative therapies to patients with serious, incapacitating, and life-threatening genetic disorders.